Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

Current Opinion in Investigational Drugs

Volumn 11, Issue 4, 2010, Pages 455-463

  Johnson, Kathryn M S ^a  

^a BELOIT COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DUTOGLIPTIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; URINARY TRACT INFECTION;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; PROTEASE INHIBITORS;

EID: 77950126863     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Schirra J, Kuwert P, Leicht P, Arnold R, Goke B, Katschiniski M PROC ASSOC AM PHYSICIANS 1997 109 1 84-97
2. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Hansen L, Deacon CF, Orskov C, Holst JJ ENDOCRINOLOGY 1999 140 11 5356-5363
3. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Xu G, Stoffers DA, Habener JF, Bonner-Weir S DIABETES 1999 48 12 2270-2276
4. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M DIABETOLOGIA 2002 45 2 195-202
5. Metabolic Diseases World Summit 2005. James S IDRUGS 2005 8 9 704-707
6. Preclinical development of PHX1149, an orally available, potent and selective DPP4 (dipeptidyl peptidase) inhibitor. Li X, Winn DT, O'Farrell AM, Mcneil M, McNamara P, Hanway D, Cherrington JM, Campbell DA DIABETES 2006 55 6 Suppl 1 Abs 538-P
7. Phenomix initiates phase II clinical trial of PHX1149 for type 2 diabetes and presents PHX1149 data at ADA. Phenomix Corp Press Release 2006 June 08
8. PHX1149, an orally available, potent and selective dipeptidyldipeptidase 4 (DPP4) inhibitor: Two week dosing study in normal volunteers. Guler H-P, Juarez JC, Van Vliet A, Aboufarha K, Cherrington JM, Campbell DA, Li X, Hanway D, O'Farrell AM DIABETES 2006 55 6 Suppl 1 Abs 2017-PO
9. PHX1149, an orally available, potent and selective dipeptidyldipeptidase 4 (DPP4) inhibitor: First in human single dose study in overweight and obese volunteers. Guler H-P, Juarez JC, Van Vliet A, Aboufarha K, Cherrington JM, Campbell DA, Li X, Hanway D, O'Farrell AM DIABETES 2006 55 6 Suppl 1 Abs 2018-PO
10. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD DIABETES CARE 2004 27 11 2628-2635
11. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He HB, Ippolito DE et al DIABETES 2005, 54 10 2988-2994
12. Effects of PHX1149, a selective DDP4 inhibitor, in subjects with type 2 diabetes mellitus. Phenomix Protocol 201 Study Group, Guler H-P DIABETOLOGIA 2007 50 Suppl 1 Abs 09-LB
13. Drug Discovery and Development of Innovative Therapeutics - IBC's 12th Annual World Congress (Part I), Boston, MA, USA, 6-9 August 2007. Harwood HJ IDDB MEETING REPORT 2007 August 6-9
14. Biology of incretins: GLP-1 and GIP. Baggio LL, Drucker DJ GASTROENTEROLOGY 2007 132 6 2131-2157
15. Phenomix announces PHX1149 phase 2b clinical trial results for type 2 diabetes. Phenomix Corp PRESS RELEASE 2008 May 16
16. NCT00690638: Safety and efficacy study of dutogliptin/ PHX1149T to treat type 2 diabetes mellitus. Phenomix Corp clinicaltrials.gov 2008
17. The biology of incretin hormones. Drucker DJ CELL METAB 2006 3 3 153-165
18. Takeda submitted a new drug application for alogliptin in Japan for treatment of type 2 diabetes. Takeda Pharmaceutical Co Ltd PRESS RELEASE 2008 September 29
19. Phenomix and Forest Laboratories to collaborate on development and commercialization of dutogliptin in diabetes. Forest Laboratories Inc Press Release 2008 October 23
20. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. DeFronzo RA, Okerson T, Viswanathan P, Guan XS, Holcombe JH, MacConell L CURR MED RES OPIN 2008 24 10 2943-2952
21. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. Amori RE, Lau J, Pittas AG JAMA-J AM MED ASSOC 2007, 298 2 194-206
22. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. Vilsboll T, Agerso H, Krarup T, Holst JJ J CLIN ENDOCRINOL METAB 2003 88 1 220-224
23. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD DIABETES CARE 2005 28 5 1092-1100
24. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Farilla L, Bulotta A, Hirshberg B, Li Calzi SL, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R ENDOCRINOLOGY 2003 144 12 5149-5158
25. Gastric emptying glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA J CLIN ENDOCRINOL METAB 1996 81 1 327-332
26. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM DIABETES 2000 49 5 741-748
27. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE DIABETES OBESITY METAB 2008 10 11 1057-1061
28. Boehringer Ingelheim's diabetes pipeline continues to advance as the company announces conclusion of robust phase III pivotal trials programme for linagliptin. Boehringer Ingelheim Corp PRESS RELEASE 2009 September 28
29. The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. Garcia-Soria G, Gonzalez-Galvez G, Argoud GM, Gerstman M, Littlejohn III TW, Schwartz SL, O'Farrell AM, Li X, Cherrington JM, Bennett C, Guler H-P DIABETES OBESITY METAB 2008 10 4 293-300
30. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: Double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li XQ, Hanway D, Li JK, Guler H-P CLIN THER 2007 29 8 1692-1705
31. 2nd quarter consolidated financial results for the period ended September 30, 2009. Mitsubishi Tanabe Pharma Corp 2ND QUARTER REPORT 2009 October 29
32. PHX1149, a selective DPP4 inhibitor, improves postprandial blood glucose control in patients with type 2 diabetes. Guler H-P; Phemomix Protocol 201 Study Group DIABETOLOGIA 2007 50 Suppl 1 Abs 0114
33. 28th Annual JPMorgan Healthcare Conference (Part IV), San Francisco, CA, USA, 11-14 January 2010. Gale SA, Croasdell G IDDB MEETING REPORT 2010 January 11-14
34. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. Perley MJ, Kipnis DM J CLIN INVEST 1967 46 12 1954-1962
35. New interpretation of oral glucose tolerance. McIntyre N, Holdsworth CD, Turner DS LANCET 1964 2, 7349, 20-21
36. The [pre-] history of the incretin concept. Creutzfeldt W REGUL PEPT 2005 128 2 87-91
37. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Vilsboll T, Krarup T, Madsbad S, Holst JJ REGUL PEPT 2003 114 2-3 115-121
38. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ J CLIN ENDOCRINOL METAB 2003 88 6 2706-2713
39. Additive insulinotropic effects of exogenous synthetic human gastric-inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W J CLIN ENDOCRINOL METAB 1993 76 4 912-917
40. The physiological role of GLP-1 in human: Incretin, ileal brake or more? Schirra J, Goke B REGUL PEPT 2005 128 2 109-115
41. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM AM J PHYSIOL 1999 277 3 Pt 2 R910-R916
42. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA J CLIN ENDOCRINOL METAB 2003 88 6 2719-2725
43. Intraportal GLP.-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels Johnson KMS, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD AM J PHYSIOL - ENDOCRINOL METAB 2007 293 4 E1085-E1091
44. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM BR J NUTR 2004 91 3 439-446
45. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Perfetti R, Zhou J, Doyle ME, Egan JM ENDOCRINOLOGY 2000 141 12 4600-4605
46. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Vilsboll T, Agerso H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S, Krarup T, Holst JJ REGUL PEPT 2006 137 3 168-172
47. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Mentlein R, Gallwitz B, Schmidt WE EUR J BIOCHEM 1993 214 3 829-835
48. What do we know about the secretion and degradation of incretin hormones? Deacon CF REGUL PEPT 2005 128 2 117-124
49. The intersection of safety and adherence: New incretinbased therapies in patients with type 2 diabetes mellitus. Zarowitz BJ, Conner C PHARMACOTHERAPY 2009 29 12 Pt 2 55S-67S
50. Liraglutide in type 2 diabetes: From pharmacological development to clinical practice. Rossi MC, Nicolucci A ACTA BIOMED 2009 80 2 93-101
51. NCT00850239: Safety and efficacy study of dutogliptin/ PHX1149T in subjects with type 2 diabetes mellitus on a background medication of metformin. Phenomix Corp clinicaltrials.gov 2009 1071452 Diabetes. WHO INTERNET SITE 2009 November Fact sheet No 312
52. Product pipeline. Phenomix Corp COMPANY WORLD WIDE WEB SITE 2010 February 03
53. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune response. Vora K, Porter G, Peng R, Cui Y, Pryor K, Eiermann G, Zaller D BMC IMMUNOL 2009 10 19
54. Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis. Williams-Herman D, Round D, Swern A, Musser B, Davies M, Stein P, Kaufman K, Amatruda J BMC ENDOCR DISORD 2008 8 14
55. Standards of medical care in diabetes - 2010. American Diabetes Association DIABETES CARE 2010 33 Suppl 1 S11-S61
56. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: A 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Pattzi HMR, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler H-P DIABETES OBESITY METAB 2010 12 4 348-355